Abstract
Four commercially available enzyme immunoassay (EIA) kits were evaluated in comparison with the plaque reduction neutralization (PRN) test for detection of measles virus antibody. The EIA kits, Enzygnost (Behring), Diamedix, Vidas (bioMerieux Vitek), and Measlestat (Biowhittaker), were assessed with two PRN cutoff titers: a PRN titer of 8, the lowest detectable antibody level by the PRN test under the test conditions, and a titer of 120, which has been shown to be the minimum protective antibody titer. At a PRN cutoff titer of 8, the sensitivity was 88.2, 91.1, 74.6, and 69.8% for Behring, Diamedix, Vidas, and Biowhittaker EIA tests, respectively, with negative predictive values ranging from 22.7 to 45.5%. The specificity was 93.8% for Diamedix and 100% for the rest. At a PRN cutoff titer of 120, the sensitivity and specificity, respectively, were 100 and 90.7% (Behring), 98.2 and 58.8% (Diamedix), 90.6 and 94.5% (Vidas), and 85.7 and 96.4% (Biowhittaker). At this PRN cutoff titer, the negative predictive values of all EIA tests improved considerably, ranging from 70.7 to 100%. The EIA results showed an excellent association with PRN results when the PRN titers of the test samples were either < 8 or > 1,052. Discrepancies occurred especially when testing samples having PRN titers in the range of 8 to 120, indicating lack of sensitivity of the EIA tests in detecting measles virus antibody at low levels. Maternally derived measles virus antibody at this level has been shown to interfere with measles vaccine response in children and hence has implications from the standpoint of measles immunization.(ABSTRACT TRUNCATED AT 250 WORDS)
Full Text
The Full Text of this article is available as a PDF (173.6 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Albrecht P., Ennis F. A., Saltzman E. J., Krugman S. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr. 1977 Nov;91(5):715–718. doi: 10.1016/s0022-3476(77)81021-4. [DOI] [PubMed] [Google Scholar]
- Albrecht P., Herrmann K., Burns G. R. Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods. 1981 Dec;3(5):251–260. doi: 10.1016/0166-0934(81)90062-8. [DOI] [PubMed] [Google Scholar]
- Atkinson W. L., Orenstein W. A., Krugman S. The resurgence of measles in the United States, 1989-1990. Annu Rev Med. 1992;43:451–463. doi: 10.1146/annurev.me.43.020192.002315. [DOI] [PubMed] [Google Scholar]
- Chen R. T., Markowitz L. E., Albrecht P., Stewart J. A., Mofenson L. M., Preblud S. R., Orenstein W. A. Measles antibody: reevaluation of protective titers. J Infect Dis. 1990 Nov;162(5):1036–1042. doi: 10.1093/infdis/162.5.1036. [DOI] [PubMed] [Google Scholar]
- Cremer N. E., Cossen C. K., Shell G., Diggs J., Gallo D., Schmidt N. J. Enzyme immunoassay versus plaque neutralization and other methods for determination of immune status to measles and varicella-zoster viruses and versus complement fixation for serodiagnosis of infections with those viruses. J Clin Microbiol. 1985 Jun;21(6):869–874. doi: 10.1128/jcm.21.6.869-874.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Forsey T., Heath A. B., Minor P. D. The 1st International Standard for anti-measles serum. Biologicals. 1991 Jul;19(3):237–241. doi: 10.1016/1045-1056(91)90042-i. [DOI] [PubMed] [Google Scholar]
- Hummel K. B., Erdman D. D., Heath J., Bellini W. J. Baculovirus expression of the nucleoprotein gene of measles virus and utility of the recombinant protein in diagnostic enzyme immunoassays. J Clin Microbiol. 1992 Nov;30(11):2874–2880. doi: 10.1128/jcm.30.11.2874-2880.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mast E. E., Berg J. L., Hanrahan L. P., Wassell J. T., Davis J. P. Risk factors for measles in a previously vaccinated population and cost-effectiveness of revaccination strategies. JAMA. 1990 Nov 21;264(19):2529–2533. [PubMed] [Google Scholar]
- Neumann P. W., Weber J. M., Jessamine A. G., O'Shaughnessy M. V. Comparison of measles antihemolysin test, enzyme-linked immunosorbent assay, and hemagglutination inhibition test with neutralization test for determination of immune status. J Clin Microbiol. 1985 Aug;22(2):296–298. doi: 10.1128/jcm.22.2.296-298.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ratnam S., Chandra R., Gadag V. Maternal measles and rubella antibody levels and serologic response in infants immunized with MMR II vaccine at 12 months of age. J Infect Dis. 1993 Dec;168(6):1596–1598. doi: 10.1093/infdis/168.6.1596-a. [DOI] [PubMed] [Google Scholar]
- Weigle K. A., Murphy M. D., Brunell P. A. Enzyme-linked immunosorbent assay for evaluation of immunity to measles virus. J Clin Microbiol. 1984 Mar;19(3):376–379. doi: 10.1128/jcm.19.3.376-379.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
- de Souza V. A., Pannuti C. S., Sumita L. M., Albrecht P. Enzyme-linked immunosorbent assay (ELISA) for measles antibody. A comparison with haemagglutination inhibition, immunofluorescence and plaque neutralization tests. Rev Inst Med Trop Sao Paulo. 1991 Jan-Feb;33(1):32–36. doi: 10.1590/s0036-46651991000100007. [DOI] [PubMed] [Google Scholar]